10/28/2009

King Pharmaceuticals has received a complete-response letter from the FDA for its heart-imaging agent CorVue. The drugmaker said it will respond to the agency's concerns about the drug, which failed to win an FDA panel's recommendation this year.

Full Story:
Reuters

Related Summaries